Biomarker signals designed for clinical relevance.
Embryo selection and transfer timing are central decisions in IVF. Our platform combines microRNA analysis with bioinformatics to develop molecular tools that complement clinical assessment. Each test requires its own validation.
CultMed Test is our lead development and commercialization priority. It analyzes microRNAs in the medium used to culture a blastocyst, typically collected on day 5.
The test is being developed to assess embryo competence and implantation potential, providing additional information to support embryo selection. Collection does not require removing cells from the embryo.
Success Test analyzes microRNAs in maternal peripheral blood plasma to investigate biological signals associated with readiness for implantation.
Its sampling schedule, reporting turnaround and clinical use are being evaluated through a separate development and validation program.
Investigational statusBoth tests are in development and validation. They are not presented as established predictors of IVF success or as tests of fetal health.
Next: collaborate on sample collection for LDT validation.
